Clinical Study On Treatment Of Ventricular Extrasystole Of Mild Or Moderate Cardiac Functional Insufficiency With Shengsong Yangxin Capsule: A Randomized, Placebo, Controlled Trial

Objective: in this clinical study, we evaluated the curative effects of ShengsongYangxin Capsule to ventricular extrasystole (VE) of mild or moderate cardiac functionalinsufficiency. At the same time, we also observed its adverse effects in order to evaluateits safety.Method: there were60patients in total with mild or moderate cardiac functionalinsufficiency accompanied by ventricular extrasystole in our hospital attending thisclinical study. The60patients were randomly allocated to2groups according to randomnumber table. One group was received Shensong Yangxin Capcures, and the other groupreceived the placebo. Each group had the same time of the therapy, which is12weeks.The clinical efficiency had been observed based on the decrease of ventricularextrasystoles in24-hour Dynamic Electrocardiography(DCG) and the abatement ofclinical symptoms.Recults:30subjects of the experimental group after treatment:21subjects’reduction rate of ventricular extrasystoles was more than50%,6subjects’ reductionrate was below50%,3subjects’ ventricular extrasystole number had increasedcompared with those before treatment; the number of ventricular extrasystole aftertreatment is1470.60±938.73, the number of ventricular extrasystole after treatmentthan that before treatment reduced1704.67±1447.91.30subjects of the control groupafter treatment:11subjects’ reduction rate of ventricular extrasystoles was morethan50%,12subjects’ reduction rate was below50%,7subjects’ ventricular extrasystole number had increased compared with those before treatment; the number ofventricular extrasystole after treatment is2752.70±2226.81, the number of ventricularextrasystole after treatment than that before treatment reduced675.30±852.23. Thedifference between the two groups in the general clinical data had no statisticalsignificance (p>0.05). In the experimental group, the reduction of the number aftertreatment of the ventricular extrasystole in24hours dynamic electrocardiogram withingroup comparisons had the statistical significance (p<0.05), so did the control group,and both of the two groups had the decrease of ventricular extrasystole. However thecomparison between two groups of the reduction of the number of ventricularextrasystoles had statistical significance (p<0.05), and the experimental group wassignificantly reduced compared with the control group. The difference of the curativeeffect of clinical symptoms between the two groups was statistically significant(p<0.05), and the curative effect of experimental group was superior to the controlgroup. During this experiment process, there was no obvious clinical adverse reactionoccurring to the2groups.Conclusion:①Shensong Yangxin Capsule can effectively reduce the number ofventricular extrasystole of chronic mild or moderate cardiac functional insufficiency.②Shensongyangxin Capsule can efficiently alleviate the clinical symptoms of thechronic mild or moderate cardiac functional insufficiency accompanied by ventricularextrasystole, such as palpitation, fatigue, dizziness;③There was no adverse effectsoccurring in this trial process, which was significantly related to ShensongyangxinCapsule. So it is reasonable to put forward that the clinical application is safe.